SCHEMBL23218393

SCHEMBL23218393

CCOC(=O)Cc1ccccc1OCc1ccc(Br)c2oc(Cl)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXAS1 P24557 1/20 0.40
NPC1 O15118 1/20 0.40
DUSP3 P51452 3/20 0.39
PTPN5 P54829 3/20 0.39
PTPN11 Q06124 3/20 0.39
CTDSP1 Q9GZU7 3/20 0.39
CFD P00746 1/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.37
PKM P14618 1/20 0.36
POLB P06746 2/20 0.36
CASP6 P55212 1/20 0.36
NOD2 Q9HC29 1/20 0.36
ALDH1A1 P00352 2/20 0.35
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SAE1 Q9UBE0 1/20 0.35
UBA2 Q9UBT2 1/20 0.35
FFAR4 Q5NUL3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853103 0.85 PTGDR2 (0.39) TBXAS1NPC1DUSP3PTPN5PTPN11
SCHEMBL23218407 0.85 PTGDR2 (0.39) TBXAS1NPC1DUSP3PTPN5PTPN11
SCHEMBL29592646 0.83 TBXAS1 (0.43) TBXAS1NPC1CFDPTGDR2PKM
SCHEMBL23219179 0.83 TBXAS1 (0.43) TBXAS1NPC1CFDPTGDR2PKM
SCHEMBL21438612 0.81 CFD (0.42) TBXAS1NPC1CFDTHRATHRB
SCHEMBL23219098 0.79 TBXAS1 (0.40) TBXAS1NPC1DUSP3PTPN5PTPN11
SCHEMBL29591267 0.79 TBXAS1 (0.40) TBXAS1NPC1DUSP3PTPN5PTPN11
SCHEMBL23219252 0.78 TBXAS1 (0.39) TBXAS1DUSP3PTPN5PTPN11CTDSP1
SCHEMBL29592062 0.78 TBXAS1 (0.39) TBXAS1DUSP3PTPN5PTPN11CTDSP1
SCHEMBL23218880 0.77 TBXAS1 (0.40) TBXAS1NPC1DUSP3PTPN5PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB TBXAS1 963/4885NPC1 324/4885DUSP3 3863/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB TBXAS1 392/4885NPC1 311/4885DUSP3 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.